abp-450
Recombinant proteinexperimental
Clinical trial activity
4 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2021 (NCT04845178)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Synaptosomal-associated protein 25INHIBITOR
SNAP25 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05016661 | Phase 2 | Sep 30, 2021 | Aeon Astron Europe B.V., Dartmouth University, PPD, Yeshiva University |
| NCT04871451 | Phase 2 | May 3, 2021 | Aeon Astron Europe B.V., Baylor University, PPD, Rush University |
| NCT04849988 | Phase 2 | Mar 29, 2021 | Aeon Astron Europe B.V., Baylor University, PPD, Rush University |
| NCT04845178 | Phase 2 | Mar 1, 2021 | Aeon Astron Europe B.V., Dartmouth University, PPD, Yeshiva University |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aeon Astron Europe B.V. | For profit | 4 | 4 | 1 | 2021 |
| PPD | For profit | 4 | 0 | 1 | 2021 |
| Baylor University | Academic/Hospital | 2 | 0 | 1 | 2021 |
| Dartmouth University | Academic/Hospital | 2 | 0 | 1 | 2021 |
| Rush University | Academic/Hospital | 2 | 0 | 1 | 2021 |
| Yeshiva University | Academic/Hospital | 2 | 0 | 1 | 2021 |
6 organizations
Page 1 / 1